Benjamin Rix Brooks
#138,113
Most Influential Person Now
Researcher
Benjamin Rix Brooks's AcademicInfluence.com Rankings
Benjamin Rix Brookscomputer-science Degrees
Computer Science
#6457
World Rank
#6809
Historical Rank
Computational Linguistics
#1120
World Rank
#1134
Historical Rank
Machine Learning
#2103
World Rank
#2130
Historical Rank
Artificial Intelligence
#2361
World Rank
#2401
Historical Rank
Download Badge
Computer Science
Benjamin Rix Brooks's Degrees
- Masters Computer Science Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Benjamin Rix Brooks Influential?
(Suggest an Edit or Addition)Benjamin Rix Brooks's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis (2000) (4514)
- El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis (1994) (2040)
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis (1995) (1651)
- Mutations in UBQLN2 cause dominant X-linked juvenile and adult onset ALS and ALS/dementia (2011) (1071)
- Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. (1995) (914)
- Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) (1999) (474)
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability (1998) (471)
- Controversies and priorities in amyotrophic lateral sclerosis (2013) (462)
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study (2017) (341)
- Progressive multifocal leukoencephalopathy. (1984) (274)
- Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years (2000) (261)
- Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence‐based review) (1999) (238)
- Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? (2014) (232)
- Practice Parameter: The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology (1999) (229)
- Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial (2014) (214)
- Consensus guidelines for the design and implementation of clinical trials in ALS (1999) (206)
- Structural brain correlates of emotional disorder in multiple sclerosis. (1986) (203)
- Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia (2010) (192)
- Home ventilation for amyotrophic lateral sclerosis patients (1993) (191)
- Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine (2004) (188)
- Disease activity and emotional state in multiple sclerosis (1983) (187)
- Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect (2010) (164)
- Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial (2014) (156)
- Hypoglossal, trigeminal, and facial motoneuron involvement in amyotrophic lateral sclerosis (1988) (146)
- Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood cerebrospinal fluid barrier for norepinephrine (1977) (142)
- Defining and Diagnosing Involuntary Emotional Expression Disorder (2006) (141)
- Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study (2002) (133)
- A diagnostic index of active demyelination: Myelin basic protein in cerebrospinal fluid (1980) (132)
- Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials (2004) (116)
- Multiple orofacial indices in amyotrophic lateral sclerosis. (1993) (114)
- Relationships between speech intelligibility and the slope of second-formant transitions in dysarthric subjects (1989) (107)
- Quantitative description of the dysarthria in women with amyotrophic lateral sclerosis. (1992) (106)
- Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials (2019) (99)
- Impairment of speech intelligibility in men with amyotrophic lateral sclerosis. (1990) (94)
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]. (2001) (94)
- Subcortical reorganization in amyotrophic lateral sclerosis (2006) (92)
- Amyotrophic lateral sclerosis. A case-control study following detection of a cluster in a small Wisconsin community. (1990) (89)
- Speech deterioration in amyotrophic lateral sclerosis: a case study. (1991) (84)
- Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases (1983) (80)
- Natural history of ALS (1996) (78)
- Emotional disturbance in multiple sclerosis patients: validity of the General Health Questionnaire (GHQ) (1981) (78)
- Design of clinical therapeutic trials in amyotrophic lateral sclerosis. (1991) (66)
- Spongiform polioencephalomyelopathy caused by a murine retrovirus. I. Pathogenesis of infection in newborn mice. (1980) (64)
- Linkage analysis in familial amyotrophic lateral sclerosis (1989) (63)
- Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial (2003) (63)
- Clinical epidemiology of amyotrophic lateral sclerosis. (1996) (63)
- Correlation of specific virus-astrocyte interactions and cytopathic effects induced by ts1, a neurovirulent mutant of Moloney murine leukemia virus (1993) (60)
- PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions (2013) (60)
- The Neuromediator Glutamate, through Specific Substrate Interactions, Enhances Mitochondrial ATP Production and Reactive Oxygen Species Generation in Nonsynaptic Brain Mitochondria* (2009) (57)
- Power wheelchair prescription, utilization, satisfaction, and cost for patients with amyotrophic lateral sclerosis: preliminary data for evidence-based guidelines. (2010) (56)
- Supported treadmill ambulation for amyotrophic lateral sclerosis: a pilot study. (2010) (55)
- Adult-onset acid maltase deficiency. Morphologic and biochemical abnormalities reproduced in in cultured muscle. (1976) (55)
- CEREBROSPINAL-FLUID LYMPHOCYTE POPULATIONS AND IMMUNE COMPLEXES IN ACTIVE MULTIPLE SCLEROSIS (1980) (51)
- Outcomes research in amyotrophic lateral sclerosis: Lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database (2009) (49)
- The Role of Axonal Transport in Neurodegenerative Disease Spread: A Meta-Analysis of Experimental and Clinical Poliomyelitis Compares with Amyotrophic Lateral Sclerosis (1991) (49)
- A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS (2014) (46)
- Managing amyotrophic lateral sclerosis: Slowing disease progression and improving patient quality of life (2009) (46)
- Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis (1987) (45)
- Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production. (1981) (44)
- Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method (2004) (43)
- Quality improvement in neurology: Amyotrophic lateral sclerosis quality measures (2013) (43)
- A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis (2018) (43)
- Functional magnetic resonance imaging (fMRI) clinical studies in ALS--paradigms, problems and promises. (2000) (41)
- Cerebrospinal fluid myelin basic protein in hydrocephalus. (1983) (41)
- Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis (2020) (40)
- Metabolic and functional differences between brain and spinal cord mitochondria underlie different predisposition to pathology. (2011) (40)
- Diagnostic dilemmas in amyotrophic lateral sclerosis (1999) (40)
- Quality improvement in neurology: Amyotrophic Lateral Sclerosis Quality Measures (2014) (38)
- Acute posterior multifocal placoid pigment epitheliopathy associated with cerebral vasculitis. (1988) (38)
- Murine neurotropic retrovirus spongiform polioencephalomyelopathy: acceleration of disease by virus inoculum concentration (1979) (38)
- Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. (1996) (37)
- Microarray analysis of peripheral blood lymphocytes from ALS patients and the SAFE detection of the KEGG ALS pathway (2011) (36)
- Risk factors in the early diagnosis of ALS: North American epidemiological studies (2000) (34)
- Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies. (1987) (33)
- Pathophysiology of Cerebrospinal Fluid Immunoglobulins (1980) (32)
- Eculizumab improves fatigue in refractory generalized myasthenia gravis (2019) (32)
- Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis (2019) (31)
- Relationship between cerebrospinal fluid norepinephrine and blood pressure in neurologic patients. (1980) (31)
- Demonstration of thyrotropin-releasing hormone immunoreactivity in neurons of the mouse spinal dorsal horn (1986) (31)
- A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS (2020) (30)
- CuZnSOD and MnSOD immunoreactivity in brain stem motor neurons from amyotropic lateral sclerosis patients (1997) (28)
- Methyl Vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death. (2011) (28)
- Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. (1995) (28)
- A Summary of the Current Position of TRH in ALS Therapy a (1989) (27)
- Cerebrospinal fluid acid‐base and lactate changes after seizures in unanesthetized man (1975) (26)
- Validation of robust tools to measure sialorrhea in amyotrophic lateral sclerosis: A study in a large French cohort (2013) (24)
- Cerebrospinal fluid GABA reductions in seizure patients evoked by cerebellar surface stimulation. (1977) (24)
- Slow viral infections. (1979) (23)
- Effect of Bovine Serum Albumin on Mitochondrial Respiration in the Brain and Liver of Mice and Rats (2010) (23)
- Frontiers in Clinical Neuroscience (2004) (23)
- In Vitro Effects of Cholesterol β-d-Glucoside, Cholesterol and Cycad Phytosterol Glucosides on Respiration and Reactive Oxygen Species Generation in Brain Mitochondria (2010) (22)
- Computerized axial tomography (1975) (22)
- ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab (2020) (22)
- Cerebrospinal Fluid γ-Aminobutyric Acid Correlation with Cerebrospinal Fluid and Blood Constituents and Alterations in Neurological Disorders (1980) (21)
- Misdiagnosis of Multiple Sclerosis (1985) (20)
- Earlier is better: the benefits of early diagnosis. (1999) (20)
- Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS CARE Study Group. (2000) (19)
- CSF viral antibodies. Evaluation in amyotrophic lateral sclerosis and late-onset postpoliomyelitis progressive muscular atrophy. (1979) (19)
- Cellular immunity and hepatitis-associated-antigen liver disease. (1972) (19)
- Cerebrospinal fluid acid‐base and lactate changes after seizures in unanesthetized man (1975) (19)
- Defining optimal management in ALS: from first symptoms to announcement. (1999) (19)
- Power Wheelchair Use in Persons With Amyotrophic Lateral Sclerosis: Changes Over Time (2015) (19)
- Alteration from T- to B-cell tropism reduces thymic atrophy and cytocidal effects in thymocytes but not neurovirulence induced by ts1, a mutant of Moloney murine leukemia virus TB. (1991) (18)
- Elevations in cerebrospinal fluid norepinephrine during unilateral and bilateral cerebellar stimulation in man. (1977) (18)
- Versailles minimal dataset for diagnosis of ALS: a distillate of the 2nd Consensus Conference on accelerating the diagnosis of ALS. Versailles 2nd Consensus Conference participants. (2000) (17)
- Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. (2018) (17)
- Patient Teaching Manuals Improve Retention of Treatment Information— A Controlled Clinical Trial In Multiple Sclerosis (1986) (16)
- Functional scales: Summary (2002) (15)
- Epidemic heat stroke in a midwest community: risk factors, neurological complications and sequelae. (1997) (15)
- A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson’s disease (2011) (14)
- Cerebrospinal fluid GABA variations with seizure type and cerebellar stimulation in man (1980) (14)
- Vestibular deficits leading to disequilibrium and falls in ambulatory amyotrophic lateral sclerosis. (2014) (14)
- PRISM: A Novel Tool to Prospectively Estimate the Prevalence of Pseudobulbar Affect Symptoms (2013) (14)
- Neurotoxic injury pathways in differentiated mouse motor neuron-neuroblastoma hybrid (NSC-34D) cells in vitro--limited effect of riluzole on thapsigargin, but not staurosporine, hydrogen peroxide and homocysteine neurotoxicity. (2012) (14)
- Cellular and Humoral Immune Responses in Human Cerebrospinal Fluid (1983) (14)
- Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis (2010) (13)
- Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium (2018) (13)
- Lymphocyte Subpopulations in Human Cerebrospinal Fluid (1980) (13)
- Myopathic Dropped Head Syndrome: An Expanding Clinicopathological Spectrum (2007) (13)
- Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study (2019) (12)
- Neurotransmitter, Metabolite, and Cyclic Nucleotide Alterations in Cerebrospinal Fluid of Seizure Patients (1980) (12)
- Myelin Basic Protein in Cerebrospinal Fluid Index of Active Demyelination (1980) (12)
- The LO-BaFL method and ALS microarray expression analysis (2012) (12)
- Involuntary Emotional Expression Disorder: Treating the Untreated (2007) (12)
- Randomized parallel placebo controlled pilot study of intravenous trh administration in amyotrophic lateral sclerosis patients increased strength and functional ability (1985) (12)
- Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis. (2017) (12)
- What are the implications of early diagnosis? Maintaining optimal health as long as possible. (1999) (11)
- Disease‐modifying drug therapies (2004) (11)
- Blood-to-cerebrospinal fluid barrier for cyclic adenosine monophosphate in man. (1977) (11)
- Clinical evaluation of ALS drugs (1997) (11)
- ALS standard of care consensus (1997) (10)
- Extracellular Cyclic Nucleotide Metabolism in the Human Central Nervous System (1980) (10)
- Excitotoxicity hypothesis. Discussion (1996) (10)
- Norepinephrine reductions in cerebrospinal fluid in man after electrical stimulation and degeneration of the caudate nucleus. (1976) (9)
- Age-dependent in vitro restriction of mouse neurotropic retrovirus replication in central nervous system-derived cells from susceptible Fv-1nn mice. (1981) (9)
- Myelin Basic Protein in Cerebrospinal Fluid (1980) (9)
- Cyclic nucleotide metabolism in neuromuscular disease. (1976) (9)
- American Academy of Neurology evidence-based review): Report of the Quality Standards Subcommittee of the Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an (2006) (9)
- Murine leukemia virus induced central nervous system diseases. (1992) (9)
- Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis (2020) (9)
- Isokinetic assessment in ALS. (1987) (8)
- MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. (2021) (8)
- Problems in shortening the time to confirmation of ALS diagnosis: lessons from the 1st Consensus Conference, Chicago, May 1998. (2000) (7)
- Dropped head syndrome (1997) (7)
- Cerebrospinal Fluid Immunoglobulins (1980) (7)
- Development of physical forms of unintegrated retroviral DNA in mouse spinal cord tissue during ts1-induced spongiform encephalomyelopathy: elevated levels of a novel single-stranded form in paralyzed mice (1995) (7)
- Whole-genome association studies of sporadic amyotrophic lateral sclerosis: are retroelements involved? (2009) (7)
- Motor Neuron Disease (1990) (7)
- Viral hepatitis type B presenting with seizure. (1977) (7)
- Delayed immune response in chorea‐amyotrophy with spherocytosis (1988) (6)
- Thyrotropin releasing hormone uptake into serum and cerebrospinal fluid following intravenous or subcutaneous administration. (1988) (6)
- Decreased spinal cord cGMP in murine (wobbler) spontaneous lower motor neuron degeneration. (1978) (6)
- Cerebrospinal fluid norepinephrine and free γ-aminobutyric acid in amyotrophic lateral sclerosis (1980) (6)
- Spinal cord metabolic changes in murine retrovirus-induced motor neuron disease (1983) (6)
- Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. (2019) (6)
- Neuroreality I. Dedicated Demolition of the Decade of the Brain: The Genuine Threat to Neurologic Research From the Animal Radical Right (1995) (6)
- PULMONARY EFFECTS OF THYROTROPIN-RELEASING HORMONE IN AMYOTROPHIC LATERAL SCLEROSIS (1984) (6)
- Spinal seizures following intravenous contrast in a patient with a cord AVM (1981) (6)
- Treatment of pseudobulbar affect in ALS (2005) (6)
- Low cerebrospinal fluid GABA concentrations in epileptic patients: variations with respect to seizure type and chronic cerebellar stimulation (1979) (6)
- The Oral Secretion Scale and Prognostic Factors for Survival in Subjects With Amyotrophic Lateral Sclerosis (2020) (6)
- ALS-Plus — Where does it begin, where does it end? (2014) (5)
- Neuropeptide degradation by large vessel and microvessel-derived endothelial cells in vitro: cell surface catabolism of thyrotropin releasing hormone (TRH) (1989) (5)
- Stage of prolonged survival in ALS (2018) (5)
- X-linked Dominant ALS (1998) (5)
- Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686] (2022) (5)
- Modification of non-invasive ventilation for the advanced amyotrophic lateral sclerosis patient during the COVID-19 pandemic - do it now (2020) (5)
- Zidovudine [AZT] myotoxicity: quantitative separation of AZT effects on proliferation and differentiation of muscle cells in vitro. Lack of myotoxicity potentiation by retrovirus. (1999) (4)
- Problems in shortening the time to confirmation of ALS diagnosis: lessons from the 1st Consensus Conference, Chicago, May 1998 (2000) (4)
- Phthalazinol, thrombocytopenia, and amyotrophic lateral sclerosis. (1980) (4)
- Issues in clinical trial design II (1996) (4)
- Thyrotropin-releasing hormone (TRH) degradation in NIH:N mouse cerebral cortex and spinal cord (1986) (4)
- Hypercaloric enteral nutrition in Amyotrophic Lateral Sclerosis: a randomized double-blind placebo-controlled trial (2014) (4)
- Debating the possibility of earlier diagnosis of patients with amyotrophic lateral sclerosis (2000) (4)
- Cyclic nucleotide metabolism in neurological disease. (1976) (4)
- Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis (2022) (4)
- Effects of Various Disease States and Immunosuppressive Drugs (1980) (3)
- DROPPED HEAD SYNDROME. AUTHORS' REPLY (1997) (3)
- Nonimmunoglobulin Proteins in Human Cerebrospinal Fluid (1989) (3)
- Effect of prednisone therapy on cerebrospinal fluid immunoglobulins and lymphocytes in chronic idiopathic relapsing polyneuropathy (CIRPN) and other neuromuscular disorders. (1977) (3)
- Increased Fiber Density after Subcutaneous TRH in Amyotrophic Lateral Sclerosis (ALS) Patients (1989) (3)
- Frontotemporal Hypometabolism in Amyotrophic Lateral Sclerosis‐Dementia Complex (1993) (3)
- Neuroreality I (1995) (3)
- Intravenous thyrotropin releasing hormone in amyotrophic lateral sclerosis: autonomic effects. (1987) (3)
- Effect of orientation on spatiotemporal contrast sensitivity in multiple sclerosis (1994) (3)
- Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19 (2021) (3)
- Pathogenesis of spongiform changes in murine retrovirus polioencephalomyelopathy. (1979) (2)
- Serum Creatinine, a Biomarker for Muscle Mass in Amyotrophic Lateral Sclerosis (ALS), Predicts Loss of Ambulation Measured by ALS Functional Rating Scale-Revised Walking Item Score (ALSFRS-Rw) (P4.085) (2014) (2)
- Rapid separation of tritiated thyrotropin-releasing hormone and its catabolic products from mouse and human central nervous system tissues by high-performance liquid chromatography with radioactive flow detection. (1989) (2)
- ts1-Induced spongiform encephalomyelopathy: physical forms of high-mobility DNA in spinal cord tissues of paralyzed mice are products of premature termination of reverse transcription (1996) (2)
- A revision to the United States national ALS registry’s algorithm to improve Case-Ascertainment (2022) (2)
- Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool (2021) (2)
- Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch (2022) (2)
- MURINE RETROVIRUS INDUCED SPONCIFORM ENCEPHALOMYELOPATHY: AN ULTRASTRUCTURAL STUDY (1978) (2)
- Disease Severity and Disease Trajectory of Amyotrophic Lateral Sclerosis (ALS) Patients at Frist Clinic Visit Measured Prospectively with "ALS Dashboard" – A Six-Domain (Cognition, Affect, Bulbar, Respiratory, Arm, Leg) Staging System – Comparison of Two Cohorts (P07.088) (2013) (1)
- Cyclic nucleotides and therapeutic perspectives. By G. Cehovic and G. A. Robison, 256 pp, Pergamon Press, New York, NY, 1979. $47.00 (1980) (1)
- Evaluation of a Health State Staging System Defined by Loss of Independence in Amyotrophic Lateral Sclerosis: Assessment in a Second Dataset (2013) (1)
- Seizure-Induced Metabolic Alterations in Human Cerebrospinal Fluid (1980) (1)
- A Study To Evaluate Safety, and Tolerability of Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis (S25.005) (2012) (1)
- 17 – Progressive Multifocal Leukoencephalopathy (2007) (1)
- Psychometric Properties of Rapid Word-Based Rate Measures in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Comparisons With Syllable-Based Rate Tasks. (2021) (1)
- Synthesis of Virus-Specific High-Mobility DNA after Temperature Upshift of SC-1 Cells Chronically Infected with Moloney Murine Leukemia Virus Mutant ts1 (2000) (1)
- Emerging directions in ALS therapeutics: palliative therapies at the advent of the twenty-first century. (1995) (1)
- Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS) (2020) (1)
- The LO-BaFL method and ALS microarray expression analysis (2012) (1)
- Edaravone administration in pivotal clinical Study 19 (2019) (1)
- Deoxyglucose uptake by mouse astrocytes: Effects of temperature and retrovirus infection (1995) (1)
- Pseudobulbar Affect in Stroke in Statesmen: The Peculiar Case of Winston Spencer Churchill (P04.003) (2012) (1)
- Autoimmunity and ALS. Discussion (1996) (1)
- Common recruitment pattern of associative motor areas in patients with degeneration of cortical pyramidal cells, as measured by fMRI (1998) (1)
- Platform Communications (2018) (0)
- Mean plasma ozanezumab concentration-time profiles following single (A) or two (B) IV infusions of ozanezumab. (2014) (0)
- Neurological Complications in the Preicteric Stage of Infectious Hepatitis. (1972) (0)
- Turner and others 2013 Controversies and priorities in Amyotrophic Lateral Sclerosis (2013) (0)
- Motor Deficit Evaluated by Timed Functional Measures Correlate with Functional Rating Scale Used in Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), but Was in Discordance in Parkinson Disease (PD) (P04.193) (2013) (0)
- Cerebrospinal fluid GABA seizure patients evoked by surface stimulation reductions in cerebellar (0)
- Safety and Tolerability of Systemic Beta-2-Adrenergic Agonist[Albuterol] as Pharmacological Therapy in Non-Invasive Ventilation[ NIV ]-supported Amyotrophic Lateral Sclerosis[ALS]Patients with Chronic Respiratory Failure (P4.079) (2014) (0)
- P2-250: A hopeful collaboration: Scientists and persons with memory loss, Alzheimer's and dementia work together to provide hope through a research-oriented data base (2008) (0)
- Dextromethorphan and Quinidine for Treatment of Pseudobulbar Affect (PBA): Time Course of PBA Episode Remission (S31.007) (2014) (0)
- Letter to the Editor: Sequence Analysis of a Neuropathogenic Variant of Moloney Murine Leukemia Virus ts1: Evidence for Recombination (2002) (0)
- Philadelphia Odd Couple - Silas Weir Mitchell - Neurologist-Novelist-Poet and Phillips Brooks - Brahmin Prophet - Sons of 19th Century Rittenhouse Square (P1.288) (2014) (0)
- Acid maltase deficiency: reincarnation in cultured muscle fibers of the typical morphological and biochemical defects. (1976) (0)
- EMPOWER Subjects with El Escorial Definite ALS Exhibited Significant Baseline Differences Independent of Disease Duration and Experienced Significantly Worse Outcomes (2013) (0)
- Walking Capacity [WalkCap] Measured by Six-Minute Walk (6MW) Does Not Demonstrate Fatigue in Patients with Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS),and Parkinson Disease (PD) (P3.071) (2014) (0)
- Decline in Walking Capacity (WC) in Ambulatory Amyotrophic Lateral Sclerosis Patients (ambALS) Is Not Accompanied by Decline in Walking Distance (WD) and Walking Velocity (WV) Recorded at 2 Minutes Intervals during the 6 Minutes Walk Test (6MWT) (P07.087) (2013) (0)
- Electronically Augmented Timed-Up-and-Go Test (EATUG) Differentiates Sit-To-Stand (STS) Mobility and Balance in Ambulatory Individuals with Amyotrophic Lateral Sclerosis (ambALS) and Parkinson Disease (ambPD) (P3.290) (2016) (0)
- Theodore Leon ‘Ted’ Munsat MD (1930–2013) (2014) (0)
- Care of the Patient with ALS Page 3 (2003) (0)
- Thanks to Reviewers2005 (2005) (0)
- Zinc Metabolism in Amyotrophic Lateral Sclerosis (ALS): Increased Cerebrospinal Fluid Zinc Following Intravenous Ethylenediamine Tetra-acetic Acid (EDTA) or Thyrotropin Releasing Hormone (TRH) (1987) (0)
- Title Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis : a randomised , double-blind , placebo-controlled phase 2 trial (2014) (0)
- Cyclic nucleotides, phosphorylated proteins, and neuronal function. By Paul Greengard, 134 pp, illus, Raven Press, New York, 1978. $12.00 (1979) (0)
- PRISM Registry: A Novel Tool To Estimate the Prevalence of Pseudobulbar Affect Symptoms (P03.215) (2013) (0)
- UBQLN2 Mutations in ALS and ALS/Dementia: A Genetic, Functional and Histopathological Analysis (S05.006) (2012) (0)
- PRISM registry: A novel tool to assess the prevalence of pseudobulbar affect symptoms in people with Alzheimer's disease (2013) (0)
- Increased Loss of 180 Degree/Second Isokinetic Torque Early in the Course of Amyotrophic Lateral Sclerosis (ALS): Correlation with Stepping and Walking Velocity on Functional Testing (1987) (0)
- Development of measurement techniques. Discussion (1996) (0)
- THEME 6 THERAPEUTIC STRATEGIES (2011) (0)
- Prevalence of Restless Leg Syndrome in Skin Biopsy Proven Small Fiber Neuropathy (5243) (2020) (0)
- Validation of the Six Minute Walk Test (6MWT) in Ambulatory Amyotrophic Lateral Sclerosis (ALS) Patients (P01.107) (2012) (0)
- Clinico-pathologic phenotype of familial ALS with a novel exon 4/codon 100 SOD1 gene mutation in an Afro-American family (1997) (0)
- Title: Sit to Stand (STS) - Maneuver: Construct Validity of a Novel Measure of Lower Extremity (LE) Function in ALS Patients (P7.193) (2015) (0)
- Cerebrospinal Fluid Noradrenergic and Behavioral Alterations Associated with Stimulation and Atrophy of the Caudate Nucleus (1980) (0)
- Preconditions for the activation of the inferior part of the premotor cortex in humans: an fMRI study. (1998) (0)
- Familial Amyotrophy, Neuropathy, Chorea, and Dementia with Spherocytosis/Elliptocytosis: A New Syndrome (1987) (0)
- Thyrotropin releasing hormone uptake into serum and cerebrospinal fluid following intravenous or subcutaneous administration. (1988) (0)
- Primary Lateral Sclerosis in Relation to Other Motor Neuron Diseases (2002) (0)
- PATHOGENESIS OF MURINE RETROVIRUS INDUCED SPONGIOFORM ENCEPHALOMYELOPATHY (1978) (0)
- Amyotrophic Lateral Sclerosis (ALS) with Laboratory Abnormalities of Unknown Significance (LAUS) --Where Does It Begin and Where Does It End? (P4.144) (2015) (0)
- Henry Agard Wallace - The First Vice-President to Develop Amyotrophic Lateral Sclerosis and the Early ALS Research Program at the National Institutes of Health - "Reflections of an ALSer" (P2.399) (2016) (0)
- A spreadsheet calculator for the diagnosis of ALS (2018) (0)
- At-Home Telespirometry [AHT] in Amyotrophic Lateral Sclerosis [ALS] (P8-8.003) (2023) (0)
- Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (2019) (0)
- MURINE NEUROTROPIC RETROVIRUS: INFECTION OF DISSOCIATED MOUSE EMBRYONIC CENTRAL NERVOUS SYSTEM CULTURES IN VITRO (1980) (0)
- Amyotrophic Lateral Sclerosis Quality Measures (S46.006) (2014) (0)
- Use of Veterans Specific Activity Questionnaire [VSAQ] to Estimate Exercise Tolerance in Ambulatory Amyotrophic Lateral Sclerosis (ambALS) Patients (P2.071) (2014) (0)
- Amyotrophic lateral sclerosis (ALS) with laboratory abnormalities of unknown significance (LAUS): where does it begin and where does it end? (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Benjamin Rix Brooks?
Benjamin Rix Brooks is affiliated with the following schools:
